



Effect of Smoking on Diabetes Mellitus

Parth Chawla^{a*#} and Meghali Kaple^{b†}

^a *Department of Biochemistry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India.*

^b *Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India.*

Authors' contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i61A35114

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/79848>

Review Article

Received 22 October 2021
Accepted 27 December 2021
Published 28 December 2021

ABSTRACT

As a genetic and environmental influences, environmental, and behavioral variable, diabetes has become one of the most frequent metabolic diseases in modern society. As a result of this study, It is possible that smoking's impact on vascular disease and diabetes predisposition might be better understood. Numerous studies (not only those including people with diabetes) smoking has been demonstrated to have significant health consequences, and it seems that the health risks faced by those with diabetes are at least on par with those faced by the general population. Several studies have unequivocally shown that people with diabetes who smoke are more likely to have macrovascular problems and are more likely to die early. Microvascular problems and type 2 diabetes are both linked to smoking, which may have an impact on the onset of both conditions. Cigarettes have been found to be a risk factor for both the shift from normal blood glucose levels to impaired glucose tolerance and for acquiring type 2 diabetes. Although many possibilities have been advanced, the processes underlying the link between smoking and the development of diabetes remain unclear. Preventing macrovascular complications and reducing microvascular disease in diabetes are two of the most significant benefits of smoking cessation, according to the most recent research. Nicotine and Smoking exposure have been related to an increased risk of type 2 diabetes in population-based research, and clinical and preclinical investigations have shed light on how these factors affect composition of the body, insulin sensitivity, and beta cell activity. In order to reduce one's risk of diabetes, smoking cessation is recommended as a preventative measure. The aim of the current review is to describe the adverse effects of smoking on diabetes.

[#]Student,

[†]Ass. Professor,

*Corresponding author: E-mail: akashchawla937@gmail.com;

Keywords: Cigarette smoking; complications; diabètes; insulin.

1. INTRODUCTION

There are almost 422 million people worldwide with diabetes mellitus, which causes 1.5 million fatalities each year, and 17.5 million extra deaths are caused by indirect causes each year [1]. In contrast to insulin resistance, the beta cell mass and efficiency diminish with time in type 2 diabetic patients. For battle against Type 2 Diabetes, early lifestyle adjustment is still the best way to reduce disease prevalence and mortality [2]. T2D is 30–40 percent more likely to occur in active smokers than in non-smokers, according to the 2014 Surgeon General's Report, which suggests that smoking cessation is a vital public health approach to battle the worldwide pandemic of diabetes. It is well accepted that smoking is a risk factor for type 2 diabetes, and the World Health Organization recommends that people avoid or quit smoking as part of their healthy lifestyles [3]. Because of this, smoking is not presently considered a modifiable risk factor for diabetes development by both the ADA and the IDF [4,5]. Cigarette smoking has been linked to an increased risk of type 2 diabetes (T2D) in population-based studies and clinical and preclinical studies, and we summarize these findings in this review. We also discuss the methods by which nicotine affects body health metabolism and glucose homeostasis.

People with diabetes should consider quitting smoking as one of the first step of process of healing that can be easily implemented with monetary benefits. Smoking cessation is one of the most critical strategies advised by the American Diabetic Association in reducing diabetes complications. In spite of the fact that smoking is proven to reduce weight, it is linked to central obesity. One of the many chemicals found in tobacco smoke is arsenic that, in addition to harming -cell function directly, Free radical processes are triggered, vascular homeostasis is disrupted, and the vascular endothelium is impaired [6].

2. SMOKING AND DIABETES HAVE A NEGATIVE CORRELATION

Several genetic, environmental, and behavioral variables increases the risk of diabetes, which is the most prevalent metabolic condition. According to a number of epidemiological studies, smoking cigarettes is a substantial risk factor for acquiring type 2 diabetes.

In adults, the long-term Insulin Resistance Atherosclerosis Study showed a clear link between cigarette smoking and diabetes. Nearly 1,000 healthy, non-diabetic people were investigated in the research under review. A total of 25% of the participants in the research were smokers, whereas 14% were nonsmokers with diabetes. When anthropometric, behavioral, metabolic, gender, racial, and hypertension-related characteristics are taken into consideration, smokers are more likely to acquire type 2 diabetes than nonsmokers. In addition, smokers with normal glucose tolerance were shown to have a greater chance of developing diabetes. Type 2 diabetes risk was also linked to smoking duration. High blood sugar, insulin resistance, and hypertension are all risks associated with smoking cigarettes for long periods of time [7,8]. Cigarette smoking and diabetes have been linked by epidemiological data.

Smoking is associated to the development of insulin resistance in several published studies (T2D). Persons who consumed 26 or more cigarettes in 24 hours had a 95 percent confidence interval (CI) of 1.25 to 3.03 times the risk of incident diabetes, comparable to nonsmokers. Women in this group had an increased risk of incident T2D of 1.25 (94% confidence interval: 1.00, 1.56), whereas males with a history of smoking less than 40 packs per year had an increased risk of T2D of 1.28 (95% confidence interval: 1.04, 1.57) [9]. A 1.28-fold increase in the risk of developing diabetes was seen in a study of postmenopausal women in the United States who smoked an average of 16.2 cigarettes per day (95 percent CI: 1.20, 1.36). After 10 years of no smoking, the chances of developing diabetes was comparable to that of person who never smoked [10]. A comparable survey was carried out on 1,236,445 Korean males and females aged between 25 to 90 years who had been followed for a total of 14 years. Men and women with diabetes were more likely to smoke, and the risk enhanced in a dose-dependent manner with increasing daily cigarette use. Males were shown to have a greater risk than females in this study.

3. REDUCED INSULIN SECRETION

Smoking has also been shown to have a negative impact on cell function, according to clinical investigations. During a 2.8-year follow-

up period among 1,199 Japanese males aged 30 to 79, a 80-gram oral glucose tolerance test produced an insulinogenic index change of 1.09 for ex-smokers and 1.89 for people who continued smoking, compared to those who never did it. It was also shown that the number of pack years smoked had a dose-dependent influence on the cell's performance [10] When it comes to assessing the function of the cells in the body, Ostgren and colleagues discovered that present nicotine smokers had lower HOMA-scores than never smokers (57.1 vs. 91.1; 95 percent CI: 17.8–43.5, p 0.001). Even after accounting for differences factors (age, BMI, alcohol utilization, and regular exercise, this variance remained important [11].

Compared to non-pharmacological procedures, varenicline has been considered to be an effective smoking cessation aid, with abstinence rates as much as two- or three-fold greater than those achieved without the use of pharmaceutical techniques. In a similar vein, studies have indicated that bupropion, a pro government, and nicotine intramuscular injections (through a patch or gum) are more effective at inducing abstinence than placebo treatment. One study conducted by the Joint Commission found that individualized weight support and counselling may be effective in reducing post-cessation water retention. Additionally, bupropion, varenicline, and nicotine replacement therapy have all been proven to reduce weight gain abruptly during active treatment; however, it is uncertain if these treatments may assist regulate weight in the long run. Furthermore, given the evidence indicating that nicotine has an indirect influence on glucose homeostasis, it is unclear if smoking cessation regimens that incorporate nicotine agonists have a distinct impact on long-term alterations in glucose homeostasis [12]. However, in vitro stimulation of INS-1 cells with nicotine, varenicline, and bupropion resulted in lower levels of glucose-stimulated insulin secretion with each drug, indicating that more research to address these problems is required.

Smoking may potentially alter insulin sensitivity through other epigenetic pathways. There were 95 chromosomal sites where smokers' DNA methylation patterns varied from those of nonsmokers in the study conducted by Northern Sweden Health Department. Smoking-induced diabetes susceptibility may be linked to abnormal DNA methylation, since genes related with "insulin receptor binding" and "negative

regulation of glucose import" are enriched in the dataset. Several previously discovered diabetes-related genes have been linked to altered methylation patterns due to consumption of nicotine [13].

It was revealed that pancreatic islets contain neuronal nicotinic acetylcholine receptors (nAChRs). Subunits of nAChRs, such as -2, -3, -4, -5, -7 and -2, were discovered on the surface of pancreatic islet cells. Chronic exposure to nicotine resulted in reduced cell insulin production, regardless of the duration of exposure (60 minutes or 48 hours). NACHRs may play a significant role in the regulation of hormone release by cells, according to the results of this study Nicotine concentrations over 1 mol/L were observed to decrease insulin production in isolated human islet cells.

Exocrine function of the pancreas in individuals with chronic pancreatitis who smoked was shown to be significantly impaired in these patients. One of the pancreas' most widely held beliefs was that the pancreas had two distinct functions: one that produced hormones and another that released digestive enzymes. In recent investigations, it has been shown that the pancreas's exocrine and exocrine functions interact. The exocrine pancreas produces and secretes enzymes via the acini receptor mechanism, for example. Smokers with chronic pancreatitis had a lower detection of blood insulin and glucagon in pancreatic samples compared to the persons who don't smoke with the same condition, with a decrease in the latter group in particular.

4. SMOKING AND DIABETES COMPLICATIONS

Smoking elevates the risk of heart disease and mortality in diabetics. When prospective studies were analyzed, it was discovered that persons who smoked had a 48% higher morbidity risk for diabetes than non-smokers, as well as for those with CHD, an ischemic stroke, and myocardial infarction (44%)(52 percent).Cardiovascular disease, stroke, and proteinuria are all more likely to occur if you smoke more cigarettes per day.

A total of twenty smokers with a smoking habit of more than a year, combined oral glucose tolerance tests after nicotine and in the lack of smoking showed that smoking impaired glucose tolerance and insulin sensitivity [14]. Clamp

investigations in patients with diabetes indicated that smokers have poorer whole-body glucose clearance compared to non-smokers. Data presents that nicotine has a direct influence on glucose homeostasis. According to these findings, hyperglycemic-hyperinsulinemia clamp tests done on patients with known T2D indicated reduced insulin action from both active smoking and acute transdermal nicotine patch delivery.

Active exposure has been linked to decrease in appetite and weight reduction in several studies. Smoking cessation, on the other other, is often connected with an increase in weight. Smoking cessation has also been related to an increased incidence of type 2 diabetes in several studies. This is most likely due to greater weight gain associated with nicotine withdrawal, and the elevated risk of T2D was sharpest in the first three years after smoking cessation. Previous research has revealed that there is substantial variation in the size of weight increase after cessation, with the biggest weight gain often seen in those who consume the greatest number of cigarettes per day on average. Studies of gender-related variations in post-cessation fluid retention (PCWG) have produced mixed findings, with some studies indicating more weight increase in males and others indicating greater weight gain in women after cessation of smoking. According to self-reported data from the NHANES research, recent quitters who may have stopped smoking within the previous year had an average PCWG of roughly 1.4 kg (95 percent confidence interval: 0.8 to 2.0). As a result of this research, normal and overweight persons were shown to be at the highest risk of weight increase, whereas obese individuals were found to be at a low but statistically significant risk of weight loss. Another sedentary category of smokers saw a mean one-year weight increase of between 3.3 and 3.9 kg, according to the research. While it is true that the effects of smoking cessation on glucose homeostasis are frequently confounded by the presence of weight gain, at least one study has proven that short-term smoking cessation of 1–2 weeks was sufficient to reverse defects in insulin sensitivity and skeletal muscle insulin signalling in both males and females in their adolescent years. To understand how these factors vary over time, longer-term research are required to be undertaken [15].

There are 2 types-

1) Microvascular

2) Macrovascular

Microvascular: Neuropathy, nephropathy and retinopathy are all early signs of microvascular disease in smokers. It's possible that smoking's negative impact on kidney disease is unrelated to its impact on blood sugar levels. Even 30 years ago, smokers with diabetes were more likely to develop diabetic kidney damage than nonsmokers. There is an increased risk of acquiring micro- or macroalbuminuria in patients with diabetes who smoke (GFR) [16-19]. More than 30 pack years of smoking increased the risk of developing proteinuria by 2.78 (95 percent confidence interval: 1.34–5.76) and 3.20 (95 percent confidence interval: 1.74–5.86) times, respectively, over non-smokers. This study found that those who had a short duration of diabetes and had effective blood pressure control had a strong link to proteinuria from smoking. Smokers are more likely to develop microalbuminuria, which progresses to overt proteinuria and eventually renal failure, than nonsmokers. Diabetes people with this condition who smoked were at the same risk of developing renal damage as diabetics with type 2 diabetes, the study found. In a recent study, researchers discovered that smokers with type 1 diabetes are more likely than nonsmokers with type 2 diabetes to develop severe kidney insufficiency. Patients with type 1 diabetes, on the other hand, show a stronger link between cigarette smoking and kidney injury.

Macrovascular: Heart disease and coronary heart disease (CHD) are major side effects of type 2 diabetes, and clinical CVD may begin before diabetes ever develops. One theory holds that CVD and type 2 diabetes are caused by the same risk factors, one of which is smoking cigarettes. The lethality but also ischemic stroke risk of persons with diabetes who inhale is substantially larger than the non-smoking population, however quitting smoking significantly reduces that risk.. In the World Health Organization Multi-National Study of Inflammatory Diseases in Dyslipidemia cohort, researchers found that smoking enhanced the blood cholesterol levels but not stroke in persons with type 1 and type 2 diabetes. Poll after poll has shown that those with type 2 diabetes who smoke are at an increased risk of developing coronary heart disease. Women with type 2 diabetes who smoke had significantly higher incidence and coronary heart disease (CHD) rates, according to data from the Nursing staff' Health Interview survey. Tobacco users who

smoke one to 14 cigarettes a day have a 1.65 relative risk of developing heart disease compared to non-smokers, while those who smoke 15 or more cigarettes a day have a 2.68 project risks [20-23].

A methodical review and meta-analysis of cohorts analyzed the association between smoke exposure and an increased risk of death and myocardial infarction (mi in mellitus. The RRs for overall mortality and cardiovascular mortality were 1.55 (1.46–1.64) and 1.49 (1.29–1.71), respectively, whereas the RRs for total CVD, coronary heart disease, stroke, and peripheral artery disease were each 1.44 (1.34–1.54) and the RR for heart failure was 1.43 (1.19–1.72). In addition, among type 1 diabetics aged 18 to 28, smoking cigarettes was connected to an increased risk of mortality and macrovascular complications. After controlling for age and gender, People with the condition who inhale are significantly more likely to be treated than those who do not inhale. [OR: 3.13; 95 percent confidence interval CI: 1.48–6.61]. [24-34]

5. CONCLUSIONS

However, epidemiological research demonstrates no correlation between nicotine and smoking and anthropometric, sugar levels, or pancreatic beta cell activity. Further information on the cellular mechanism through which nicotine and smoking exposure affect metabolic homeostasis has been gained. As a result of this lack of comprehensive research, we still don't know how tobacco usage affects the pancreatic cell. Smoking should be regarded a recognized and controllable risk factor for diabetes development, regardless of these unknowns, according to a thorough evaluation of the existing research. Therefore, whether or not a person smokes should be taken into account while being tested for diabetes. Diabetes may be prevented by quitting smoking and managing one's post-smoking weight. Diabetes patients continue to smoke as least as often as the general population despite overwhelming evidence of the dangers of smoking. In this population, there may be a lack of effective patient education, which might be a contributing factor. Those who have diabetes or vascular issues might lower their chance of acquiring more difficulties by progressively quitting smoking. However, the optimal way to stop smoking for those who have a high risk of diabetes is still unknown.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. World Health Organization. [Accessed February 2017]
Available:http://www.who.int/topics/diabetes_mellitus/en/
2. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta (GA); 2014.
3. World Health Organization. [Accessed February 2017] Global Report on Diabetes.
Available:<http://www.who.int/diabetes/global-report/en/>
4. Auerbach S, Filer D, Reif D, Walker V, Holloway AC, Schlezinger J, et al. Prioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast High-Throughput Data. *Environmental health perspectives*. 2016; 124:1141–54. [PubMed: 26978842]
5. [Accessed February 2017] International Diabetes.
Available: www.idf.org
6. Saeed AA. Association of tobacco products use and diabetes mellitus-results of a national survey
7. among adults in saudi arabia. *Balkan medical journal*. 2012;29:247–51. [PubMed: 25207009]
8. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *Jama*. 2007; 298:2654–64. [PubMed: 18073361]
9. Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett WC. Prospective study of cigarette smoking, alcohol use, and the risk of diabetes in men. *BMJ*. 1995; 310:555–9. [PubMed:7888928]
10. Shi L, Shu XO, Li H, Cai H, Liu Q, Zheng W, et al. Physical activity, smoking, and

- alcohol consumption in association with incidence of type 2 diabetes among middle-aged and elderly Chinese men. *PLoS One*. 2013;8:e77919. [PubMed: 24223743]
11. Luo J, Rossouw J, Tong E, Giovino GA, Lee CC, Chen C, et al. Smoking and diabetes: does the increased risk ever go away? *American journal of epidemiology*. 2013;178:937–45. [PubMed: 23817918]
 12. Iqbal D, Burhan IW, Choudhary RK, Alaidarous M, Alshehri BM, Banawas S, Mir SA. Analysis between Cigarette and Shisha Smokers for Early Atherogenesis: A Cardiovascular Disease, *Journal of Pharmaceutical Research International*. 33(41A):175-186. DOI: 10.9734/jpri/2021/v33i41A32316.
 13. Jee SH, Foong AW, Hur NW, Samet JM. Smoking and risk for diabetes incidence and mortality in Korean men and women. *Diabetes care*. 2010;33:2567–72. [PubMed: 20823342]
 14. Sargeant LA, Khaw KT, Bingham S, Day NE, Luben RN, Oakes S, et al. Cigarette smoking and glycaemia: the EPIC-Norfolk Study. *European Prospective Investigation into Cancer. International journal of epidemiology*. 2001;30:547–54. [PubMed: 11416081]
 15. Clair C, Bitton A, Meigs JB, Rigotti NA. Relationships of cotinine and self-reported cigarette smoking with hemoglobin A1c in the U.S.: results from the National Health and Nutrition Examination Survey, 1999–2008. *Diabetes Care*. 2011;34:2250–5. [PubMed: 21836101]
 16. Somm E. Nicotinic cholinergic signaling in adipose tissue and pancreatic islets biology: revisited function and therapeutic perspectives. *Arch Immunol Ther Exp (Warsz)*. 2014;62:87–101. [PubMed: 24276790]
 17. Phillips WD. Acetylcholine receptors and the cytoskeletal connection. *Clinical and experimental pharmacology & physiology*. 1995;22:961–5. [PubMed: 8846518]
 18. Zoli M, Picciotto MR. Nicotinic regulation of energy homeostasis. *Nicotine Tob Res*. 2012;14:1270–90. [PubMed: 22990212]
 19. Kimura K, Tanida M, Nagata N, Inaba Y, Watanabe H, Nagashimada M, et al. Central Insulin Action Activates Kupffer Cells by Suppressing Hepatic Vagal Activation via the Nicotinic Alpha 7 Acetylcholine Receptor. *Cell Rep*. 2016; 14:2362–74. [PubMed: 26947072]
 20. Epifano L, Di Vincenzo A, Fanelli C, Porcellati F, Perriello G, De Feo P, et al. Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus. *Eur J Clin Pharmacol*. 1992;43:257–63. [PubMed: 1425888]
 21. Chiba M, Masironi R. Toxic and trace elements in tobacco and tobacco smoke. *Bull World Health Organ*. 1992;70:269–75. [PubMed: 1600587]
 22. Rhee SY, Hwang YC, Woo JT, Chin SO, Chon S, Kim YS. Arsenic exposure and prevalence of diabetes mellitus in Korean adults. *Journal of Korean medical science*. 2013;28:861–8. [PubMed: 23772150]
 23. Pan WC, Seow WJ, Kile ML, Hoffman EB, Quamruzzaman Q, Rahman M, et al. Association of low to moderate levels of arsenic exposure with risk of type 2 diabetes in Bangladesh. *American journal of epidemiology*. 2013;178:1563–70. [PubMed: 24049161]
 24. Feseke SK, St-Laurent J, Anassour-Sidi E, Ayotte P, Bouchard M, Levallois P. Arsenic exposure and type 2 diabetes: results from the 2007–2009 Canadian Health Measures Survey. *Health promotion and chronic disease prevention in Canada*. 2015; 35:63–72. [PubMed: 26083521]
 25. Moon SS. Association of lead, mercury and cadmium with diabetes in the Korean population: the Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010. *Diabetic medicine: a journal of the British Diabetic Association*. 2013; 30:e143–8. [PubMed: 23278294]
 26. Thayer KA, Heindel JJ, Bucher JR, Gallo MA. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. *Environmental health perspectives*. 2012; 120:779–89. [PubMed: 22296744]
 27. Fujiyoshi A, Miura K, Kadowaki S, Azuma K, Tanaka S, Hisamatsu T, et al. Lifetime cigarette smoking is associated with abdominal obesity in a community-based sample of Japanese men: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). *Prev Med Rep*. 2016;4:225–32. [PubMed: 27413686]
 28. Jameel, Patel Zeeshan, Sham Lohiya, Amol Dongre, Sachin Damke, and Bhavana B. Lakhkar. Concurrent Diabetic Ketoacidosis and Pancreatitis in Paediatric Acute Lymphoblastic Leukemia Receiving

- L-Asparaginase. BMC Pediatrics. 2020; 20:1.
Available:<https://doi.org/10.1186/s12887-020-02136-3>.
29. Kaple, Meghali Narayan, Chandrashekhar C. Mahakalkar, Anita Kale, and Swati Shambharkar. Correlation of Metal Ions in Diabetic Patients. Journal of Clinical and Diagnostic Research. 2020;14(5):BC14–16.
Available:<https://doi.org/10.7860/JCDR/2020/43798.13730>.
30. Thakare, Pratiksha, And Ruchira Ankar. "To Assess The Knowledge Regarding Prevention Of Sign And Symptoms Of Diabetic Ketoacidosis Among Diabetes Patients In Selected Hospitals Of Wardha District." International Journal Of Modern Agriculture. 2020;9(3):125–30.
31. Thakare PS, Ankar R. To Assess the Knowledge Regarding Signs and Symptoms of Diabetic Ketoacidosis and Its Prevention among Diabetes Patients in Wardha District, Maharashtra, India. Journal of Evolution of Medical And Dental Sciences-Jemds. 2021;10(19):1413–6.
32. Thool AR, Dhande NK, Daigavane SV. Study of Correlation between Renal Function Test and Severity of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus. Journal of Evolution of Medical and Dental Sciences-Jemds. 2021;10(20):1511–4.
33. David P, Yeola M, Ankar R. Efficacy of Nursing Skin Care Protocol on Prevention of Skin Related Problems among Newly Diagnosed Diabetic Patients. Journal of Pharmaceutical Research International. 2021;33(31A):1–8.
34. Kumar CA, Mahakalkar C, Yeola (Pate) M. Assessment of Risk Factors in the Causation & Outcomes of Diabetic Foot. Journal of Pharmaceutical Research International. 2021;33(37A):264–70.

© 2021 Chawla and Kaple; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<https://www.sdiarticle5.com/review-history/79848>